

1 **Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern**
2 **recognition molecules**

3
4 Matteo Stravalaci^{1,2*}, Isabel Pagani^{3*}, Elvezia Maria Paraboschi^{1,2}, Mattia Pedotti⁴, Andrea
5 Doni¹, Francesco Scavello¹, Sarah N. Mapelli¹, Marina Sironi¹, Luca Varani⁴, Milos
6 Matkovic⁴, Andrea Cavalli^{4,5}, Daniela Cesana⁶, Pierangela Gallina⁷, Nicoletta Pedemonte⁷,
7 Valeria Capurro⁷, Nicola Clementi⁸, Nicasio Mancini⁸, Pietro Invernizzi^{9,10}, Rino
8 Rappuoli^{11,12}, Stefano Duga^{1,2}, Barbara Bottazzi¹, Mariagrazia Uguccioni^{4,2}, Rosanna
9 Asselta^{1,2}, Elisa Vicenzi^{3,§}, Alberto Mantovani^{1,2,13,§}, Cecilia Garlanda^{1,2,§}

10

11

12 ¹IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano (Milan), Italy;

13 ²Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4,
14 20090 Pieve Emanuele (Milan), Italy;

15 ³Viral Pathogenesis and Biosafety Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

16 ⁴Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona,
17 Switzerland.

18 ⁵Swiss Institute of Bioinformatics, Lausanne, Switzerland

19 ⁶San Raffaele Telethon Institute for Gene Therapy (SR-Tiget); IRCCS, San Raffaele
20 Scientific Institute, Milan, Italy.

21 ⁷UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genova

22 ⁸Laboratory of Microbiology and Virology, IRCCS Scientific Institute and Vita-Salute San
23 Raffaele University, Milan Italy.

24 ⁹Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of
25 Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ¹⁰European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo

27 Hospital, Monza, Italy

28 ¹¹Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, Siena, Italy.

29 ¹²Faculty of Medicine, Imperial College London, London, UK.

30 ¹³The William Harvey Research Institute, Queen Mary University of London, Charterhouse

31 Square, London EC1M 6BQ.

32 * equally contributed

33 §Corresponding authors: cecilia.garlanda@humanitasresearch.it,

34 alberto.mantovani@humanitasresearch.it, vicenzi.elisa@hsr.it

35

36 **Summary**

37 The humoral arm of innate immunity includes diverse molecules with antibody-like functions,
38 some of which serve as disease severity biomarkers in COVID-19. The present study was
39 designed to conduct a systematic investigation of the interaction of humoral fluid phase pattern
40 recognition molecules (PRM) with SARS-CoV-2. Out of 10 PRM tested, the long pentraxin
41 PTX3 and Mannose Binding Lectin (MBL) bound the viral Nucleoprotein and Spike,
42 respectively. MBL bound trimeric Spike, including that of variants of concern, in a glycan-
43 dependent way and inhibited SARS-CoV-2 in three *in vitro* models. Moreover, upon binding
44 to Spike, MBL activated the lectin pathway of complement activation. Genetic polymorphisms
45 at the MBL locus were associated with disease severity. These results suggest that selected
46 humoral fluid phase PRM can play an important role in resistance to, and pathogenesis of,
47 COVID-19, a finding with translational implications.

48

49 **Introduction**

50 SARS-CoV-2 is a highly pathogenic coronavirus and the causative agent of the current
51 Coronavirus disease-2019 (COVID-19) pandemic (Hartenian et al., 2020; Wu et al., 2020; Zhu
52 et al., 2020). Innate immunity is credited to play a fundamental role in this condition and may
53 eradicate the infection in its early phases, before adaptive immune responses take place. In
54 severe forms of the disease, uncontrolled activation of innate and adaptive immunity results in
55 hyperinflammatory responses, which affect the lung and blood vessels, contributing to ARDS,
56 shock and multiorgan failure (Wang et al., 2020).

57 Innate immunity includes a cellular and a humoral arm (Bottazzi et al., 2010). The
58 humoral arm consists in soluble PRMs belonging to different families, which include collectins
59 [e.g. mannose binding lectin (MBL)], ficolins, pentraxins [C-reactive protein (CRP), Serum
60 amyloid P component (SAP), pentraxin 3 (PTX3)], and C1q (Bottazzi et al., 2010; Garlanda et
61 al., 2018; Holmskov et al., 2003). Humoral PRMs represent functional ancestors of antibodies
62 (ante-antibodies), as they recognize microbial components and eliminate pathogens with
63 common mechanisms that include agglutination, neutralization, activation of the complement
64 cascade and opsonization facilitating phagocytosis (Bottazzi et al., 2010). Investigations of the
65 role of humoral innate immunity in viral sensing have shown that collectins bind to envelope
66 glycoproteins on enveloped viruses, including influenza virus, human immunodeficiency virus,
67 hepatitis C virus (HCV) and herpes simplex virus, as well as to the nonenveloped rotavirus
68 (Holmskov et al., 2003). Interaction may result in opsonization, agglutination, inhibition of
69 viral fusion and entry, or complement activation, generally leading to inhibition of infection
70 (Holmskov et al., 2003). Among pentraxins, the long pentraxin PTX3 has been show to interact
71 with H3N2-subtype influenza virus type A by interacting with viral envelope hemagglutinin
72 and neuraminidase glycoproteins through a sialic acid residue on its glycosidic moiety
73 (Reading et al., 2008), with cytomegalovirus (CMV) (Bozza et al., 2006), and with the

74 coronavirus murine hepatitis virus strain 1 (MHV-1) (Han et al., 2012), preventing viral
75 infection.

76 Several lines of evidence, including genetic associations, indicate that cellular innate
77 immunity, and related cytokines and chemokines, play a key role in SARS-CoV-2 recognition,
78 antiviral resistance and, at later stages, severe disease (Merad and Martin, 2020; Pairo-
79 Castineira et al., 2021; Severe Covid et al., 2020; Zhang et al., 2020). In contrast, little
80 information is available concerning the role of the humoral arm of innate immunity in COVID-
81 19 resistance and pathogenesis, in spite of the clinical prognostic significance of CRP and
82 PTX3 (Brunetta et al., 2021; Fajgenbaum and June, 2020).

83 The present study was designed to conduct a systematic investigation of the interaction
84 of the humoral PRM with SARS-CoV-2. We found that PTX3 and MBL bound the SARS-
85 CoV-2 Nucleoprotein and Spike, respectively. MBL recognized variants of concern (VoC),
86 had antiviral activity and activated the Complement lectin pathway. Genetic polymorphisms at
87 the MBL locus were associated with disease severity. Thus, selected fluid phase PRM (ante-
88 antibodies) play an important role in resistance to, and pathogenesis of, COVID-19, a finding
89 with translational implications.

90

91 **Results**

92 **Interaction of humoral pattern recognition molecules with SARS-CoV-2 proteins**

93 To study the role of humoral PRMs in recognizing SARS-CoV-2, we first investigated
94 the interaction between humoral innate immunity molecules and SARS-CoV-2 proteins using
95 a solid phase binding assay. We first analysed pentraxins and, as shown in Figure 1A and 1B,
96 we did not observe specific binding of CRP and SAP to any of the SARS-CoV-2 proteins tested
97 (S1, S2, S protein active trimer, Nucleocapsid, Envelope protein). In contrast, PTX3 bound
98 specifically and in a dose-dependent manner to the Nucleocapsid protein, one of the most

99 abundant proteins of SARS-CoV-2 (Zeng et al., 2020) (Figure 1C). We validated this result by
100 confirming the binding of PTX3 with SARS-CoV-2 Nucleocapsid protein produced obtained
101 from different sources. PTX3 is a multimeric glycoprotein arranged in an octameric structure.
102 Each protomer is constituted of a flexible N-terminal region and a C-terminal domain with
103 homology to the short pentraxin family (Bottazzi et al., 2010). To define which portion of the
104 molecule was involved in the interaction, we compared the binding of full length PTX3 and its
105 N-terminal or C-terminal domains to SARS-CoV-2 Nucleocapsid protein. Results indicate that
106 PTX3 interacts with SARS-CoV-2 Nucleocapsid protein mainly through its N-terminal
107 domain, although with lower affinity compared to full length PTX3 (Figure 1D).

108 We next investigated the interaction between PRMs of the classical and the lectin
109 pathway of complement (C1q and the collectin MBL, respectively) and the viral proteins. As
110 shown in Figure 2A, C1q did not interact with any protein tested. In contrast, human MBL
111 bound to SARS-CoV-2 Spike protein (Wuhan strain (Wu et al., 2020), active trimer), but not
112 to the individual SARS-CoV-2 Spike subunits S1 [containing the receptor-binding domain
113 (RBD)] and S2 (containing the membrane fusion domain) (Figure 2B). We validated these data
114 by analyzing the binding of MBL to different recombinant SARS-CoV-2 Spike proteins
115 obtained from different sources or produced in house either in HEK293 cells, or CHO cells, or
116 in insect cells (Figure 2C and Extended Data Figure 1). All these preparations were bound by
117 MBL, although with some differences. Notably, when we tested a non-covalent trimer of the
118 SARS-CoV-2 Spike protein, we did not observe binding. These results indicate that a native-
119 close structure of the SARS-CoV-2 Spike protein (presumably in the trimeric conformation) is
120 indispensable for MBL recognition.

121 MBL is a member of the collectin family, a class of PRMs composed of a Ca²⁺- type
122 lectin domain (also called Carbohydrate Recognition Domain, CRD) and a collagen-like
123 domain (Holmskov et al., 2003). Thus, we analyzed the interaction of SARS-CoV-2 Spike

124 protein with other collectins involved in innate immunity, such as Collectin-12 (CLP-1) and
125 the pulmonary surfactant proteins SP-A and SP-D. We also extended the analysis to
126 recombinant Ficolin-1, -2, or -3, a family of proteins known to activate the complement lectin
127 pathway, and structurally-related to MBL. As shown in Figure 2D and 2E, in contrast with
128 MBL, CLP-1, SP-A, SP-D, and ficolins did not bind to SARS-CoV-2 Spike protein, indicating
129 that recognition of Spike is unique to MBL.

130 We further characterized the interaction of SARS-CoV-2 Spike protein with MBL by
131 Surface Plasmon Resonance (SPR). Different concentrations of recombinant, SARS-CoV-2
132 Spike protein or RBD domain were flowed onto MBL immobilized on the biosensor surface.
133 As shown in Figure 2F and Extended Data Figure 2, trimeric SARS-CoV-2 Spike protein
134 formed a stable calcium-dependent complex with nanomolar affinity ($K_D=34$ nM) whereas
135 MBL did not bind the isolated RBD, confirming the results obtained using the S1 subunit.

136 To mimic the interaction between MBL and SARS-CoV-2 Spike protein in its
137 physiological conformation in the viral envelope, we investigated the binding of viral particles
138 of SARS-CoV-2 Spike protein pseudotyped on a lentivirus vector to MBL-coated plates. The
139 interaction was determined by lysing the bound pseudovirus and measuring the lentiviral vector
140 p24 core protein by ELISA. While control lentiviral particles pseudotyped with the VSV-g
141 glycoprotein (VSV-pseudovirus) did not result in any binding, those exposing the SARS-CoV-2
142 Spike protein showed a specific interaction with MBL (Figure 3A). These data strongly suggest
143 that MBL can also interact with the SARS-CoV-2 Spike protein exposed on the virus surface.

144

145 **MBL interacts with glycosidic sites of the SARS-CoV-2 spike protein**

146 The SARS-CoV-2 Spike protein is highly glycosylated, as recently described
147 (Watanabe et al., 2020). Out of the 22 N-glycosylation sites, 8 contain oligomannose-types
148 glycans, which could be interaction sites for the MBL carbohydrate recognition domain (CRD).

149 To address this possibility, we performed a solution-based competition assay with D-mannose
150 and N-acetyl-glucosamine, two specific ligands of the lectin. As shown in Figure 3B, D-
151 mannose and N-acetyl-glucosamine inhibited MBL binding to the Spike protein, thus
152 confirming the Ca²⁺-dependent interaction between the MBL lectin domain and the glycosidic
153 sites exposed by the Spike protein. D-Glucose, a non-specific ligand of MBL, inhibited the
154 interaction only at higher concentration (Figure 3B). Based on the alignment of MBL crystal
155 structure with mannose molecules (Fig. 3C), we identified 14 putative binding sites on the
156 Spike protein (Fig. 3D). Next, we considered sites having a high (>80%) oligomannosylation
157 occupancy (Watanabe et al., 2020). This analysis provided two possible MBL binding sites,
158 namely N603, N801 and N1074 all on the same Spike chain, or N603, N1074 and N709 with
159 N709 on a neighboring chain (Figure 3E). Interestingly, in both cases, the hypothesized MBL
160 binding sites spans across the S1 and S2 region (Figure 3F) of the Spike protein providing hints
161 to a possible inhibition mechanism. These data indicate that the glycosylation state of the
162 SARS-CoV-2 Spike protein is important for its interaction with MBL.

163

164 **Interaction of MBL with Spike from VoC**

165 We then tested whether MBL recognized Spike proteins from VoC. First, we analyzed
166 whether the known 22 glycosylation sites of each protomer are affected by the reported
167 mutations. Figure 3G shows a schematic representation of the 22 positions of N-linked
168 glycosylation sequons and of 35 known mutations, indicating that none of these mutations
169 involve the glycosylation sites, and suggesting that MBL could interact with the variants with
170 the same affinity. In agreement with our binding assays, no MBL target sites are expected in
171 the RBD. We assessed by solid phase assay the interaction of MBL with the SARS-CoV-2
172 D614G Spike trimeric protein, the B.1.1.7 variant (emerged in UK), the B.1.1.28 or P.1 variant

173 (emerged in Brazil), and B.1.351 (emerged in South Africa) (Figure 3H). In agreement with
174 the *in silico* analysis, MBL bound the VoC Spike proteins tested with similar affinity.

175

176 **Complement lectin pathway activation**

177 We asked whether the interaction of MBL with Spike could activate the complement
178 lectin pathway. We incubated SARS-CoV-2 Spike protein-coated plates with human serum, or
179 C1q- or C4- or C3-depleted serum, and we assessed the deposition of C5b-9. As shown in
180 Figure 3I (left panel), incubation with either normal human serum or C1q-depleted serum
181 resulted in complement deposition mediated by SARS-CoV-2 Spike protein. Conversely,
182 incubation with a serum depleted of C4 strongly reduced C5b-9 deposition, with levels
183 comparable to those observed with heat-inactivated serum or C3-depleted serum.
184 Reconstitution of C4-depleted serum with purified C4 restored C5b-9 deposition levels similar
185 to those observed with normal human serum. To further address the role of MBL in SARS-
186 CoV-2 Spike protein-mediated complement activation, we assessed C5b-9 deposition by
187 incubating normal human serum or MBL-immunodepleted serum over captured SARS-CoV-2
188 Spike protein, either as active, or non-covalent trimer (Figure 3I, right panel). In agreement
189 with binding data, no complement deposition was observed with the non-covalent trimeric
190 Spike protein. Notably, immunodepletion of MBL from human serum resulted in a significant
191 reduction in C5b-9 deposition, which could be fully reverted by addition of rhMBL (Figure 3I,
192 right panel). These data clearly indicate that SARS-CoV-2 Spike, by interacting with MBL,
193 activates the complement lectin pathway.

194

195 **SARS-CoV-2 inhibition by MBL**

196 To validate the relevance of the interaction between MBL and SARS-CoV-2 Spike
197 protein, we investigate whether MBL inhibited SARS-CoV-2 entry in susceptible cells. We

198 first tested the effect of MBL and other soluble PRMs (10-fold serial dilution, from 0.01 to 10
199 $\mu\text{g/ml}$) on the entry of the viral particles of SARS-CoV-2 Spike protein pseudotyped on a
200 lentivirus vector in 293T cells overexpressing Angiotensin-Converting Enzyme 2 (ACE2).
201 Among the soluble PRMs tested, MBL was found to be the only molecule with anti-SARS-
202 CoV-2 activity. Spike-mediated viral entry was inhibited by 90% at the highest concentration
203 of 10 $\mu\text{g/ml}$ (34 nM) with an EC50 value of approximately 0.5 $\mu\text{g/ml}$ (1.7 nM) (Figure 4A).
204 As control, entry of lentiviral particles pseudotyped with the VSV-g glycoprotein was not
205 inhibited by MBL (Figure 4A).

206 We next tested the antiviral activity of MBL on the SARS-CoV-2 infection of lung
207 epithelial models relevant to human infections. Among a number of lung-derived epithelial cell
208 lines, Calu-3 (human lung adenocarcinoma) cells have been shown to be permissive to SARS-
209 CoV-2 infection (Chu et al., 2020). SARS-CoV-2 (D614G variant, MOI=0.1 and 1) was
210 preincubated in complete medium containing different concentrations of MBL (0.01–10
211 $\mu\text{g/mL}$; 0.034–34 nM) before incubation with Calu-3 cells. After 48 and 72 h, the infectivity of
212 SARS-CoV-2 present in cell culture supernatants was determined by a plaque-forming assay
213 in monkey-derived Vero cells. Vero cells are a handy cell line used worldwide as it is devoid
214 of the interferon (IFN) response (Desmyter et al., 1968) and, for this reason, highly supportive
215 of virus replication.

216 As shown in Extended Data Figure 3A, MBL showed a concentration-dependent inhibition
217 of SARS-CoV-2 infection of Calu-3 cells at MOI 0.1 (upper panel) and 1 (lower panel), that
218 was statistically significant at 1 and 10 $\mu\text{g/ml}$ (3.4 and 34 nM) 72 h after infection. When both
219 virus and cells were pre-incubated with the same concentrations of MBL (0.01–10 $\mu\text{g/mL}$;
220 0.034–34 nM), the antiviral activity increased significantly from 0.1 $\mu\text{g/ml}$ (0.34 nM) to the
221 top concentration of 10 $\mu\text{g/ml}$ (34 nM), 72 h post-infection (PI) (Figure 4B and Extended Data
222 Figure 3B). The calculated EC50 was 0.08 $\mu\text{g/mL}$ (0.27 nM) at 72h. Notably, MBL showed

223 a concentration-dependent inhibition of infection of Calu-3 cells also by SARS-CoV-2 variant
224 20I/501Y.V1 (B.1.1.7) at MOI 1 (Figure 4C) and MOI 0.1 (Extended Data Figure 3C), as well
225 as by 20H/501Y.V2 (B.1.351) at MOI 1 (Figure 4D).

226 Furthermore, a model of 3D-human bronchial epithelial cells (HBEC) was used to
227 test whether MBL inhibited SARS-CoV-2 replication. SARS-CoV-2 production at the
228 epithelial apical surface increased sharply at 48 h PI (not shown), reaching $48 \times 10^6 \pm 6 \times 10^6$
229 (mean \pm SEM) PFU/ml 72 h PI. Treatment of HBEC with MBL decreased viral production
230 to $4 \times 10^6 \pm 0.8 \times 10^6$ PFU/ml 72 h PI at the highest concentration of 50 μ g/ml (170 nM) (Figure
231 5A). In contrast PTX3 treatment was ineffective at inhibiting virus production (Extended
232 Data Figure 3D). We then assessed whether in these experimental conditions, MBL affected
233 inflammatory responses in HBEC upon SARS-CoV-2 infection. As shown in Extended Data
234 Figure 3E, MBL treatment inhibited the production of IL-8 and CXCL5, chemokines
235 involved in myeloid cell recruitment and activation.

236 We finally evaluated occurrence of MBL-Spike protein interaction in SARS-CoV-2
237 infected HBEC by confocal microscopy. As shown in Figure 5B and C, MBL colocalized with
238 SARS-CoV-2 Spike protein in infected cells. In 3D rendered images of the HBEC cell cultures
239 (Figure 5D and Movie S1), colocalization was preferentially associated to the apical side of
240 cytokeratin 14 positive cells. Evidence of the interaction between MBL and SARS-CoV-2
241 Spike protein in infected HBEC at molecular scale (<100 nm *XY* spatial resolution) were also
242 obtained in STED-based super-resolution microscopy (Figure 5E).

243

244 ***MBL2* haplotypes are associated with severe COVID-19**

245 MBL2 genetic variants have been shown to correlate with increased susceptibility to
246 selected infections, including SARS (Ip et al., 2005). To explore the significance of our *in vitro*
247 results in the frame of COVID-19 pandemic, we investigated the possible association of *MBL2*

248 polymorphisms with severe COVID-19 with respiratory failure in an Italian cohort of 332 cases
249 and 1,668 controls (general population). We initially focused on six SNPs known to be
250 associated with MBL2 protein levels (Table 1) (Lipscombe et al., 1992; Madsen et al., 1994;
251 Madsen et al., 1995; Sumiya et al., 1991). Surprisingly, we observed a significant difference
252 only in the frequency of the rs5030737-A allele between patients and controls (7.7% and 6.0%,
253 respectively; OR=1.43, 95%CI=1.00-2.05, P=0.049; Table 1A), which however did not survive
254 the correction for multiple testing. When we compared the frequencies of haplotypes
255 determined by all six SNPs, we found the CCGGCC haplotype frequency significantly
256 decreased in patients with severe COVID-19 (26.7% in cases, 30.4% in controls). This
257 haplotype shows a protective effect (odds ratio (OR)=0.78, 95%CI=0.65-0.95, P=0.025; Table
258 1B), consistently with the lack of the rs5030737-A allele, which is only present in the
259 CCAGCC haplotype (OR=1.38, 95%CI=1.00-1.90; P=0.078; Table 1B).

260 Though borderline, these first association results encouraged us to investigate the 1-
261 Mb-long genomic region encompassing the *MBL2* gene systematically. To this aim, we
262 performed single-SNP as well as haplotype-based association analyses using
263 genotyped/imputed data on 3,425 polymorphisms. Single-SNP association analysis revealed
264 three suggestive signals (rs150342746, OR=3.47, 95%CI=1.81-6.68, P=1.86*10⁻⁴;
265 rs10824845, OR=1.76, 95%CI=1.30-2.39, P=2.91*10⁻⁴; and rs11816263, OR=1.42,
266 95%CI=1.17-1.73, P=3.47*10⁻⁴; Table 1C; Figure 6), whereas haplotype-based analysis
267 disclosed 7 haplotypes of different lengths, from 2 to 24 SNPs, strongly associated with severe
268 COVID-19 (all surviving the correction for multiple tests; Figure 6; Table 1D). Among them,
269 the one composed of polymorphisms rs10824844-rs10824845 incorporates one of the two top-
270 markers evidenced by the single-SNP association analysis and is present in 12.2% of cases and
271 6.9% of controls (TA haplotype, OR=1.88, 95%CI=1.44-2.45, P=1.04*10⁻⁵; Table 1D). Hence,
272 we performed a meta-analysis based on the rs10824845 polymorphism by including the GHS

273 study of COVID-19 patients: this resulted in a pooled OR=1.32, 95%CI=1.15-1.52, P=9.12*10⁻
274 ⁵ (Table 1E). Notably, the rs10824845 polymorphism points to a regulatory region
275 characterized by the presence of an enhancer (GH10J052964), described as a distant modulator
276 of the *MBL2* gene, active in HepG2 cells (hepatocytes), as well as M0 (from venous blood) and
277 M1 (from cord and venous blood) macrophages (data from the GeneHancer database, available
278 through <http://www.genecards.org/>).

279

280 **Discussion**

281 Among the 10 fluid phase PRM tested in this study, only PTX3 and MBL bound SARS-
282 CoV-2 virus components. PTX3 recognized the viral Nucleoprotein and had no antiviral
283 activity. PTX3 was expressed at high levels by myeloid cells in blood and lungs and its plasma
284 levels have strong and independent prognostic significance for death in COVID-19 patients
285 (Brunetta et al., 2021; Schirinzi et al., 2021). It remains to be elucidated whether PTX3 plays
286 a role in Nucleocapsid-mediated complement activation and cytokine production (Gao et al.,
287 2020; Karwaciak et al., 2021; McBride et al., 2014).

288 MBL recognized the SARS-CoV-2 Spike protein, including that of three VoC, and had
289 antiviral activity *in vitro*. MBL had previously been shown to bind SARS-CoV Spike (Zhou et
290 al., 2010). The interaction of MBL with Spike required a trimeric conformation of the viral
291 protein, did not involve direct recognition of the RBD and was glycan-dependent, as expected.
292 Site-specific glycosylation analysis of the SARS-CoV-2 Spike protein revealed the presence
293 of various oligomannose-type glycans across the protein (Watanabe et al., 2020).

294 Molecular modelling reported here suggests that the MBL trimer interact with glycans
295 attached to the residues N603, N801 and N1074 on the same chain or N603, N709 and N1074
296 with N709 on a different chain. In both cases the hypothesized MBL binding site spans across
297 the S1 and S2 region of SARS-CoV-2 Spike, suggesting a possible neutralization mechanism.

298 The binding of MBL could prevent the detachment of the S1 region and the release of the
299 fusion peptide at position 815, thus inhibiting virus entry into host cells. However, the
300 mechanisms responsible for the antiviral activity of MBL remain to be fully defined. It is
301 noteworthy that C-type lectins have been reported to act as entry receptors (or coreceptors)
302 (Chiodo et al., 2020; Lempp et al., 2021; Lu et al., 2021) and MBL is likely to compete at this
303 level.

304

305 Interestingly, the *in silico* analysis presented here indicate that mutations in variants
306 reported until now do not affect glycosylation sites containing oligomannose-types glycans
307 potentially recognized by MBL. In addition, binding and infection experiments show that the
308 anti-viral activity of MBL is not affected by these mutations. This indicate that the
309 glycosylation sites are generally spared by selective pressure, suggesting they are essential for
310 SARS-CoV-2 infectivity. It has been recently shown that mechanisms of *in vitro* escape of
311 SARS-CoV-2 from a highly neutralizing COVID-19 convalescent plasma include the insertion
312 of a new glycan sequon in the N-terminal domain of the Spike protein, which leads to complete
313 resistance to neutralization (Andreano et al., 2020). This result further emphasizes the
314 relevance of Spike glycosidic moieties targeted by MBL in SARS-CoV-2 infectivity.

315 MBL was found to interact with Spike and have antiviral activity with an EC50 of
316 approximately 0.08 µg/ml (0.27 nM) and an affinity of 34 nM. These concentrations are well
317 in the range of those found in the blood of normal individuals (up to 10 µg/ml) which increase
318 2-3-fold during the acute phase response. MBL plasma levels in healthy individuals are
319 extremely variable, in part depending on genetic variation in the *MBL2* gene. Defective MBL
320 production has been associated with increased risk of infections, in particular in primary or
321 secondary immunodeficient children (Koch et al., 2001). In SARS, conflicting results have
322 been reported concerning the relevance of *MBL2* genetic variants in this condition (Ip et al.,

2005; Yuan et al., 2005; Zhang et al., 2005). In COVID-19, one *MBL2* SNP has been associated with development and severity of the infection (Medetalibeyoglu et al., 2021). We investigated the possible role of *MBL2* genetic variants in determining susceptibility to severe COVID-19 with respiratory failure, by exploiting the statistical power provided by haplotype analysis. Surprisingly and in contrast with a previous study (Medetalibeyoglu et al., 2021), we found only a borderline correlation between one haplotype of the 6 SNPs associated with MBL levels and frequency of severe COVID-19 cases. However, we found a total of 7 significantly associated haplotypes, distributed along the *MBL2* genomic region, often mapping in correspondence of regulatory elements (such as enhancers, promoter region, histone marks; Figure 6). Our association data are reinforced by: i) the meta-analysis results, obtained by integrating the summary statistics from a European cohort of >113,000 individuals; ii) the fact that one of our second best associations (i.e., rs10824845) maps in proximity of a cluster of suggestive signals ($P < 5 \times 10^{-4}$) identified by the COVID-19 Host Genetic Initiative (<https://www.covid19hg.org/>; results on release 4 include data from up to 33 different worldwide studies; Figure 6); iii) the Regeneron – Genetic Center database, which contains association results also for rare variants (MAF < 1%), reports a significant association ($P < 0.05$) for the rs35668665 polymorphism both with susceptibility to COVID-19 (OR=4.11, GHS cohort) and with severity of symptoms (OR=7.91, UK BioBank cohort). Interestingly, this variant maps in correspondence of the last nucleotide of *MBL2* exon 1, thus possibly interfering with the splicing process; and iv) the rs5030737 (p.Arg52Cys) polymorphism in *MBL2* has been described in the UKBiobank ICD PheWeb database (<https://pheweb.org/UKB-SAIGE/>) as a top signal in determining both “dependence on respirator [Ventilator] or supplemental oxygen” (ICD code Z99.1; $P = 2.7 \times 10^{-4}$) and “Respiratory failure, insufficiency, arrest” (ICD code J96; $P = 2.7 \times 10^{-3}$). These observations suggest that genetic variations in *MBL2*, possibly involved in the modulation of the expression of the gene in hepatocytes, and, interestingly, in

348 macrophages, could play a role in determining susceptibility to severe COVID-19 with
349 respiratory failure. Therefore genetic analysis is consistent with the view that MBL recognition
350 of SARS-CoV-2 plays an important role in COVID-19 pathogenesis.

351 Upon interaction with Spike, MBL was found to activate the lectin pathway of
352 complement, as expected. Complement has been credited an important role in the
353 hyperinflammation underlying severe disease and is considered a relevant therapeutic target
354 (Carvelli et al., 2020; Risitano et al., 2020). Therefore, as for innate immunity in general
355 including the IFN pathway (King and Sprent, 2021), MBL-mediated recognition of SARS-
356 CoV-2 may act as a double-edged sword. In early phases of the disease MBL, possibly
357 produced locally by macrophages, may serve as a mechanism of antiviral resistance by
358 blocking viral entry, whereas in advanced disease stages it may contribute to complement
359 activation and uncontrolled inflammation.

360 MBL has been safely administered to patients with cystic fibrosis and chronic lung
361 infections in which MBL deficiency contributes to pathogenesis (Garred et al., 2002; Jensenius
362 et al., 2003). Therefore, the results presented here have translational implications both in terms
363 of comprehensive genetic risk assessment and development of local or systemic therapeutic
364 approaches.

365

366

367 **Acknowledgements**

368 This work was supported by a philanthropic donation by Dolce & Gabbana fashion house (to
369 A.M., C.G., E.V.), by the Italian Ministry of Health for COVID-19 (to A.M. and C.G.), the
370 Italian Ministry of University and Research (to P.I.), by the Department of Excellence project
371 PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic, to P.I.). We
372 also thank the generous contribution of Banca Intesa San Paolo, and AMAF Monza ONLUS
373 and AIRCS for the unrestricted research funding.

374

375 **Author contributions**

376 A.M. and C.G. conceived the study in March 2021 and catalyzed the interaction between
377 different Institutions; C.G., E.V. and B.B. supervised the development of the effort; M.S. and

378 I.P. conducted the core experimental work related to binding, antiviral activity and
379 Complement activation. The genetic analysis was conducted by E.M.P. supervised by S.D.
380 and R.A.; A.D. performed the imaging analysis; M.P., L.V., M.M and A.C. performed SPR
381 analysis and modeling; S.N.M. performed the bioinformatic analysis; M.G.U., R.R., P.I.
382 provided essential tools and material; F.S., Ma.S., D.C., P.G., N.P., V.C. N.C., N.M.
383 conducted complementary experiments.

384


385 **Declaration of interests**

386 A.M., C.G. and B.B. are inventors of a patent (EP20182181) on PTX3 and obtain royalties on
387 related reagents; A.M., C.G., B.B. and E.V. are inventors of a patent (102021000002738) on
388 MBL. The other authors declare no competing interests.

389

390


391 **Figures**



392

393 **Figure 1. Interaction between pentraxins and SARS-CoV-2 proteins.** (A-C) Recombinant
394 HiS Tag SARS-CoV-2 proteins were immobilized on 96-well Nickel coated plates at different
395 concentrations. Fixed concentrations of SAP (A), CRP (B) and PTX3 (C) were incubated over
396 the captured viral proteins. Bound pentraxins were detected by ELISA with specific primary
397 antibodies. (D) Full length PTX3 or its N- or C-terminal domains were captured on 96-well
398 plates. Biotinylated SARS-CoV-2 Nucleocapsid protein was incubated at different
399 concentrations. Bound nucleocapsid was detected by ELISA using HRP-conjugated
400 streptavidin. All data are presented as mean \pm SEM of two independent experiments performed
401 in duplicate (n=4).

402



403

404 **Figure 2. Interaction of C1q, MBL, ficolins and surfactant proteins with SARS-**

405 **CoV-2 proteins.** (A-C) Recombinant HiS Tag SARS-CoV-2 proteins were immobilized on

406 96-well Nickel coated plates at different concentrations. Fixed concentrations of C1q (A), or

407 MBL (B) were incubated over the captured viral proteins. In (C), recombinant SARS-CoV-2 S


408 proteins tested were expressed in different cell types. MBL (2 µg/mL- 6.7 nM) was incubated

409 over the captured viral proteins. A-C: Bound proteins were detected by ELISA with specific

410 primary antibodies. All data are presented as mean ± SEM of two independent experiments

411 performed in duplicate (n=4). (D) MBL-, CLP-1-, SP-D-, SP-A- or (E) Ficolin-1-, Ficolin-2-

412 and Ficolin-3-coated plates were incubated with various concentrations of biotinylated SARS-
413 CoV-2 S protein. D-E: Bound S protein was detected by ELISA with HRP-conjugated
414 streptavidin (mean \pm SEM of two independent experiments in duplicate, n=4). (F) SPR shows
415 binding of recombinant full Spike protein trimer to immobilized MBL ($K_D=34$ nM, left). No
416 binding is detected in the absence of CaCl_2 (right).
417



418


419 **Figure 3. Interaction of MBL with SARS-CoV-2 S protein through its**

420 **Carbohydrate Recognition Domain (CRD). (A) MBL-coated plates were incubated with**

421 **different concentrations of viral particles of SARS-CoV-2 Spike protein (Spike-LV) or VSV-**

422 g pseudotyped on a lentivirus vector. After lysis, bound pseudovirus was quantified by
423 measuring the released p24 core protein by ELISA. Dotted line represents p24 levels measured
424 using the highest concentration of VSV-g pseudotyped lentivirus. Data are represented as mean
425 \pm SEM of two independent experiments (n=6-10). (B) Biotinylated SARS-CoV-2 S protein
426 was captured on Neutravidin coated plates. MBL (0.25 μ g/mL) was incubated over S protein,
427 alone or in the presence of different concentrations of D-mannose or N-acetyl-glucosamine or
428 D-glucose. Binding of free MBL was detected by ELISA. Data are presented as percentage of
429 bound MBL (mean \pm SEM of two independent experiments, n=4). (C) Trimeric MBL2 model
430 shows the distance of approximately 40 Å between mannose-binding sites. MBL2 subunits are
431 represented in transparent surface and cartoon, colored in cyan, blue, and dark blue; mannose
432 molecules are represented in white spheres; (D) 14 mannose-binding sites, represented as red
433 triangles, imposed onto Spike protein. Spike is represented in transparent surface and cartoon,
434 where S1 region (1-685) is colored in green, beginning of S2 region (686-815) is colored in
435 black, and S2' region is colored in white. (E) Putative binding site of MBL2. Pose with the
436 highest site-specific probability to be glycosylated with oligomannose; (F) Spike-MBL2
437 complex. Glycosylation sites are colored according to the oligomannose glycosylation
438 probability. Gold < 60%. Purple > 80% up until S2' region. Blue > 80% in the S2' region. (G)
439 Schematic representation of glycosylation sites and nucleotide substitutions in the variant
440 strains identified to date. The 8 glycosylation sites containing oligomannose-types glycans,
441 which are potential targets of MBL, are evidenced. SNPs common to all variants are in bold.
442 NTD: N terminal domain; RBD: receptor binding domain; FP: fusion peptide; HR1 and 2:
443 heptad repeat 1 and 2; cleavage sites are reported. (H) Binding of MBL to SARS-CoV-2 S
444 protein variants: recombinant SARS-CoV-2 S protein (D614G), B.1.1.7, P.1, and B.1.351
445 variants were captured onto a Nickel coated plate at different concentrations. MBL (1 μ g/mL
446 – 3.4 nM) was incubated over the captured viral proteins. Data are represented as mean \pm SEM,

447 n=3 replicates. One representative experiment out of two performed is shown for B.1.1.7. For
448 the other variants, one experiment was performed. (I) MAC (C5b-9) deposition on SARS-CoV-
449 2 Spike protein-coated plates. The assay was performed in the presence of 10% normal human
450 serum (NHS), C1qDHS, C4DHS, C4DHS reconstituted with C4, C3DHS, MBL-ID serum,
451 MBL-ID serum reconstituted with rhMBL. Mean \pm SEM of two independent experiments,
452 performed in triplicate (n=6).
453



454

455

456

457

458

459

460

461

462

463

464


465

466

Figure 4. Inhibition of SARS-CoV-2 infection by MBL. (A) Entry of lentiviral particles pseudotyped with SARS-CoV-2 Spike protein in 293T cells overexpressing ACE2 in the presence of ten-fold serial dilutions of humoral innate immunity PRMs (from 0.01 to 10 $\mu\text{g/ml}$). As control, entry of lentiviral particles pseudotyped with the VSV-g glycoprotein was tested in parallel in the presence of MBL. Percentage of control was calculated as ratio of GFP-positive cells in the presence of humoral PRMs and the GFP-positive cells in the absence of humoral PRMs. Data are means \pm SEM of three independent experiments in triplicates with the curves representing a three-parameter dose response model. (B-D) Inhibition of the infectivity of the D614G (isolate EPI_ISL_413489) (B), B.1.1.7 (C) and B.1.351 (D) SARS-CoV-2 variants by MBL in Calu-3 cells. SARS-CoV-2 (MOI=1) and Calu-3 cells were preincubated in complete medium containing different concentrations of MBL (0.01–10 $\mu\text{g/mL}$ – 0.034–34 nM) before infection. After 48 and 72 h, the infectivity of SARS-CoV-2

467 present in cell culture supernatants was determined by a plaque-forming assay in Vero cells.
468 NIL: no MBL. Mean values of two (B) or one (C, D) experiments in duplicate cell culture are
469 shown. ****p value <0.0001, ***p value <0.001, **p value <0.01 as determined by two-way
470 ANOVA with Bonferroni's correction.
471

472



473

474 **Figure 5. Inhibition by MBL of SARS-CoV-2 infection of primary respiratory cells. (A)**

475 SARS-CoV-2 production at the HBEC apical surface at 72 h PI, in the presence of 10 or 50

476 µg/ml (34 or 170 nM) MBL. Mean values of three experiments in triplicate (2 donors) or single

477 (1 donor) cell cultures are shown. A: p values were determined by one-way ANOVA with

478 Bonferroni's correction. ****: p value <0.0001, **: p value <0.01. (B-E) Colocalization of

479 SARS-CoV-2 S protein and MBL in infected HBEC. (B), Confocal analysis of the localization


480 of SARS-CoV-2 S protein (green), MBL (red) in HBEC cultures infected by SARS-CoV-2 in

481 presence or not of MBL (50 µg/ml -170 nM). Left panels, merged images of fluorescence

482 signals; right panels, single signals extracted. Representative MIP images of 4-12 Z- stacks
483 acquired in tiling modality are shown. Bar, 30 μ m. (C) Left panel: extracted signals of SARS-
484 CoV-2 S protein and MBL of (B). Right panel: colocalization rate between SARS-CoV-2 S
485 protein and MBL (10 or 50 μ g/ml - 34 or 170 nM). Each spot corresponds to a single XYZ
486 image presented as MIP. Mean \pm SE. (D) 3D rendering of B right panel, showing a blended
487 reconstruction of the localization between SARS-CoV-2 S protein and MBL in HBEC cultures.
488 Left panel, contribution of merged signals. Bar, 30 μ m. Middle panel, extracted image of signal
489 of SARS-CoV-2 S protein and MBL. Right panel, close-up image that refers to the area dashed
490 in white. (E) STED analysis of the localization of SARS-CoV-2 S protein and MBL in HBEC.
491 Left panel, merged signals of SARS-CoV-2 S protein and MBL and nucleus; right, single
492 signals extracted. Bar, 3 μ m.

493

494



495

496 **Figure 6: The *MBL2* locus: structure and main association signals with severe COVID-**
 497 **19.**

498 (A) A screenshot from the UCSC Genome browser (<http://genome.ucsc.edu/>; release Dec.
 499 2013, GRCh38/hg38) specifically highlighting the 1-Mb region surrounding the *MBL2* gene is
 500 shown. The panel reports, in order, the following tracks: i) the ruler with the scale at the
 501 genomic level; ii) chromosome 10 nucleotide numbering; iii) the UCSC RefSeq track; iv)
 502 COVID-19 risk variants from our study (lollipops show only signals at $P < 3 \times 10^{-3}$); v) COVID-
 503 19 risk haplotypes, marked by the tagging SNP, from our study (lollipops show all haplotypes
 504 reported in Table 1B and 1D); vi) COVID-19 risk variants from the COVID-19 HGI GWAS
 505 Analysis C2 (17,965 cases, 33 studies, Release 4: October 2020); vii) ENCODE data

506 (<https://www.encodeproject.org/>) for H3K27Ac, H3K4Me1, H3K4Me3 histone modifications
507 marks, all derived from 7 cell lines; viii) the GeneHancer regulatory elements track.

508 (B) The Manhattan plot of the single-SNP association analysis is reported. The horizontal line
509 represents the suggestive $P=5*10^{-5}$ significance level. SNPs showing lowest P value signals
510 are indicated by an arrow. Bonferroni threshold for significance corresponds to $P < 1.5*10^{-5}$.

511

512

513 **Table 1. Association analysis results**

514 **A. Candidate SNP association analysis**

| SNP* | rsID | Variation | A1 | MAF cases | MAF controls | OR | 95%CI | P* | Direction (A1)** |
|--------------------|------------|---|----|-----------|--------------|-------|-----------|-------|-----------------------|
| chr10:52771466:C:T | rs1800451 | p.Gly57Glu | T | 0.017 | 0.021 | 0.814 | 0.39-1.72 | 0.588 | Lowers MBL2 levels |
| chr10:52771475:C:T | rs1800450 | p.Gly54Asp | T | 0.017 | 0.15 | 1.070 | 0.83-1.39 | 0.609 | Lowers MBL2 levels |
| chr10:52771482:G:A | rs5030737 | p.Arg52Cys | A | 0.077 | 0.06 | 1.434 | 1.00-2.05 | 0.049 | Lowers MBL2 levels |
| chr10:52771701:G:A | rs7095891 | Promoter region | A | 0.221 | 0.243 | 0.827 | 0.66-1.04 | 0.104 | - |
| chr10:52771925:G:C | rs7096206 | Promoter eQTL in liver (P=1.7*10 ⁻¹⁷) | G | 0.215 | 0.205 | 1.201 | 0.96-1.51 | 0.113 | Lowers MBL2 levels |
| chr10:52772254:G:C | rs11003125 | Promoter eQTL in liver (P=9.1*10 ⁻⁶) | C | 0.342 | 0.364 | 0.886 | 0.73-1.09 | 0.236 | Increases MBL2 levels |

515 * Bonferroni threshold for significance is P < 0.008.

516 ** Direction derived from either the literature or the GTEx database (The Genotype-Tissue Expression database; <https://www.gtexportal.org/home/>).

517

518

519 **B. Haplotype analysis for candidate SNPs**

520 **(rs1800451|rs1800450|rs5030737|rs7095891|rs7096206|rs11003125)**

| Haplotype | Frequency in cases | Frequency in controls | OR | CI | P* |
|-----------|--------------------|-----------------------|-------|-------------|-------|
| CCAGCC | 0.075 | 0.060 | 1.380 | 1.000-1.903 | 0.078 |
| CCGGCC | 0.267 | 0.304 | 0.785 | 0.651-0.946 | 0.025 |
| CCGGGG | 0.216 | 0.205 | 1.190 | 0.971-1.458 | 0.130 |
| TCGACG | 0.017 | 0.0210 | 0.870 | 0.458-1.652 | 0.704 |
| CCGACG | 0.205 | 0.222 | 0.833 | 0.678-1.023 | 0.121 |
| CTGGCG | 0.166 | 0.150 | 1.090 | 0.870-1.366 | 0.501 |
| CCGGCG | 0.054 | 0.038 | 1.500 | 1.026-2.192 | 0.056 |

521 * Bonferroni threshold for significance is P < 0.05.

522

523

524 **C. Locus-wide association analysis (SNPs with P<0.0050 are shown)**

| SNP | rsID | A1 | MAF cases | MAF controls | OR | 95%CI | P* |
|---------------------|-------------|----|-----------|--------------|-------|-------------|-----------------------|
| chr10:53229424:C:T | rs150342746 | T | 0.026 | 0.008 | 3.474 | 1.808-6.676 | 1.86*10 ⁻⁴ |
| chr10:52963964:G:A | rs10824845 | A | 0.124 | 0.072 | 1.762 | 1.297-2.393 | 2.91*10 ⁻⁴ |
| chr10:53083059:C:A | rs11816263 | A | 0.386 | 0.315 | 1.422 | 1.173-1.725 | 3.47*10 ⁻⁴ |
| chr10:53104393:A:G | rs74974397 | G | 0.071 | 0.041 | 1.813 | 1.235-2.661 | 0.0024 |
| chr10:53082503:A:AT | rs71032688 | A | 0.258 | 0.191 | 1.415 | 1.128-1.776 | 0.0025 |
| chr10:53155596:C:T | rs117108247 | T | 0.069 | 0.042 | 1.750 | 1.195-2.561 | 0.0040 |

525 * Bonferroni threshold for significance is P < 1.5*10⁻⁵.

526

527

528

529

530

531

532 **D. Locus-wide haplotype analysis**

| Haplotype | Frequency in cases | Frequency in controls | OR | CI | P | P permutation* | SNPs** |
|--|--------------------|-----------------------|-------|-------------|------------------------|-----------------------|---|
| ATCGCAA | 0.006 | 0.043 | 0.133 | 0.049-0.36 | 2.26*10 ⁻⁷ | 9.99*10 ⁻⁴ | 6 SNPs, rs11344513 rs7071467 |
| CCC | 0.005 | 0.073 | 0.058 | 0.019-0.182 | 3.12*10 ⁻¹⁶ | 9.99*10 ⁻⁴ | 3 SNPs, rs17662822 rs1159798 rs1912619 |
| TCCCC | 0.000 | 0.021 | <1.00 | nc | 1.17*10 ⁻⁵ | 0.019 | 5 SNPs, rs2204344 rs12218074 rs80035245 rs79357128 rs10824836 |
| TCAGACC | 0.032 | 0.007 | 4.92 | 2.69-9 | 2.59*10 ⁻⁶ | 4.99*10 ⁻³ | 5 SNPs, rs16935439 rs147096903 rs10824839 rs11003267 rs11003268 |
| TA | 0.122 | 0.069 | 1.876 | 1.435-2.453 | 1.04*10 ⁻⁵ | 0.018 | 2 SNPs, rs10824844 rs10824845 |
| ATCCCCGC ATTGA | 0.000 | 0.040 | <1.00 | nc | 3.41*10 ⁻⁷ | 9.99*10 ⁻⁴ | 9 SNPs, rs57504125 chr10:5308418:G:A |
| AGATCCCC GCGCGTGC AACGGCT GCGGA | 0.237 | 0.170 | 1.509 | 1.235-1.844 | 3.28*10 ⁻⁶ | 4.99*10 ⁻³ | 24 SNPs, rs71032688 rs7092597 |

533 * P Value as calculated after performing 1,000 permutations to correct for multiple testing.

534 ** The number of SNPs composing the haplotype is indicated. All the SNPs forming the
535 haplotype are shown for short haplotypes (including max 5 SNPs). For more complex
536 haplotypes (including > 5 SNPs) only the first and the last SNPs are indicated.

537

538 **E. Meta-analysis for the rs10824845 polymorphism**

| Cohort | Cases (A1/A2 alleles) | Controls (A1/A2 alleles) | OR | 95%CI | P |
|----------------|-----------------------|--------------------------|------|-------------|-----------------------|
| Italian cohort | 82/582 | 241/3,095 | 1.81 | 1.392-2.353 | 9.57*10 ⁻⁶ |
| GHS cohort | 180/1,558 | 18,979/205,845 | 1.20 | 1.024-1.396 | 0.023 |
| Summary | | | 1.32 | 1.149-1.520 | 9.12*10 ⁻⁵ |

539

540 In all sub-tables the SNP column is in the format chromosome:position:reference
541 allele:alternative allele. The position refers to hg38 version of the genome.

542 A1=minor allele; A2=major allele; CI=confidence interval; MAF=minor allele frequency;
543 nc=not calculated; OR=odds ratio; rsID=reference sequence identification number;
544 SNP=single nucleotide polymorphism.

545

546

547

548 **Methods**

549 **Recombinant proteins and Antibodies**

550 Commercial and non-commercial recombinant SARS-CoV-2 proteins used in this study
551 are listed in Supplementary Table 1. Recombinant human PTX3 and its domains from CHO
552 cells were produced in house, as previously described (Bottazzi et al., 1997). Recombinant
553 human Surfactant Protein-A (SP-A) was from Origene. Recombinant human MBL, Collectin-
554 12 (CLP-1), Ficolin-1, Ficolin-2, Ficolin-3 and Surfactant Protein-D (SP-D) were from
555 Biotechne. Purified human C1q was from Complement Technology, purified CRP was from
556 Millipore and purified SAP was purchased from Abcam. Rabbit anti-PTX3 antibody was
557 produced in house (Bottazzi et al., 1997), rabbit anti-MBL Ab was purchased from Abcam.
558 Anti-C1q polyclonal antibody was purchased from Dako. Anti-CRP and anti-SAP antibodies
559 were from Merck.

560 **Binding of Humoral Pattern Recognition Molecules to SARS-CoV-2 proteins**

561 Recombinant His-Tag SARS-CoV-2 proteins were immobilized at different
562 concentrations (ranging from 6.25 to 50 pmol/mL) on 96-well Nickel coated plates (Thermo
563 Fisher Scientific) for 1 h at room temperature. Plates were then blocked for 2 h at 37°C with
564 200 µL of 2% BSA diluted in 10 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl, 2
565 mM CaCl₂ and 0.1% Tween-20 (TBST-Ca²⁺). Following blocking, plates were washed three
566 times with TBST-Ca²⁺ and incubated for 1 h at 37°C with 100 µL PTX3 (4 µg/mL – 12 nM in
567 TBST-Ca²⁺), MBL (1-2 µg/mL – 3.4-6.7 nM in TBST-Ca²⁺), C1q (4 µg/mL – 10 nM in TBST-
568 Ca²⁺), CRP (3 µg/mL – 25 nM in TBST-Ca²⁺) and SAP (4 µg/mL – 32 nM in TBST-Ca²⁺).
569 After washes, plates were incubated for 1 h at 37°C with specific primary antibodies, followed
570 by the corresponding HRP-conjugated secondary antibodies. Both primary and secondary
571 antibodies were diluted in TBST-Ca²⁺ buffer. After development with the chromogenic
572 substrate 3,3',5,5'-tetramethylbenzidine (TMB, Thermo Fisher Scientific, USA), binding was

573 detected by absorbance reading at 450 nm on a Spectrostar Nano Microplate Reader (BMG
574 Labtech, Germany). Values from blank wells were subtracted from those recorded at sample
575 wells.

576 In another set of experiments, 100 μ L of 2 μ g/mL rhMBL (6.7 nM), CLP-1 (6.7 nM),
577 Ficolin-1 (5 nM), Ficolin-2 (5 nM), and Ficolin-3 (3 nM), SP-A (3 nM) or SP-D (3.4 nM) in
578 PBS were immobilized on 96-well Nunc Maxisorp Immunoplates (Costar, USA) overnight at
579 4°C. Plates were blocked with 200 μ L of 2% BSA-TBST- Ca^{2+} for 2 h at 37°C. After washes,
580 100 μ L of biotinylated SARS-CoV-2 S protein was added at different concentrations to the
581 plates for 1 h at 37°C. Following washes, HRP-conjugated streptavidin (1:10000, Biospa) was
582 incubated for 1 h at 37°C. Specific binding was detected by TMB development, as described
583 above.

584 For competition-based experiments, biotinylated SARS-CoV-2 S protein was captured
585 on 96-wells Neutravidin coated plates for 1 h at 37°C. Plates were then incubated for 1 h at
586 37°C with 100 μ L rhMBL (0.25 μ g/mL- 0.83 nM) alone or in the presence of various
587 concentrations of D-mannose or N-acetyl-glucosamine, or D-glucose (Sigma Aldrich). Bound
588 MBL was detected by incubation with rabbit anti-MBL antibody, followed by HRP-conjugated
589 secondary antibody and TMB development, as described above.

590 For the experiments on the interaction between PTX3 domains and SARS-CoV-2
591 Nucleocapsid, PTX3 and its recombinant domains were immobilized on the wells of a 96-well
592 Nunc Maxisorp plate. Then, different concentrations of biotinylated SARS-CoV-2
593 Nucleocapsid protein were added over the captured proteins for 1 h at 37°C. Detection of
594 binding was achieved through incubation with HRP-conjugated streptavidin, as detailed above.

595 **Surface plasmon resonance (SPR) studies**

596 SPR analyses were carried out at 25 °C on a Biacore 8K instrument (GE Healthcare).
597 MBL was immobilized on the surface of a CM5 sensor chip through standard amine coupling.

598 Briefly, after activation of the surface with a mixture of 1-Ethyl-3-(3-dimethylaminopropyl)
599 carbodiimide hydrochloride and N-Hydroxysuccinimide, MBL was diluted at 50 nM in 10 mM
600 sodium acetate buffer, pH 4.5 and injected over the surface (flow rate 10 μ l/min). Free activated
601 sites were blocked by flowing 1 M Ethanolamine, pH 8.5. Final MBL immobilization levels
602 were around 4500 Resonance Units (RU, with 1 RU = 1 pg/mm²). A second surface was
603 prepared in parallel with the same procedure, but without any ligand, and used as reference.
604 Recombinant RBD and trimeric Spike were produced in EXPI293 cells and purified as reported
605 (De Gasparo et al., 2021). Increasing concentration of SARS-CoV-2 RBD or Spike protein
606 (2.5, 7.4, 22, 67, 200 and 600 nM) were injected using a single-cycle kinetics setting at a flow
607 rate of 30 μ l/min; dissociation was followed for 10 minutes. The running buffer (also used to
608 dilute samples) was 10 mM Tris-buffered saline, pH 7.4, containing 150 mM NaCl, 2 mM
609 CaCl₂ and 0.005% Tween-20. In another set of experiments, the interaction was analyzed using
610 the running buffer without CaCl₂. Analyte responses were corrected for unspecific binding and
611 buffer responses through the use of reference channels. Binding kinetics were determined by
612 fitting of the experimental curves with the Langmuir 1:1 model according to standard
613 procedures; data analyses were performed with Biacore™ Insight Evaluation Software
614 v2.0.15.12933. In the presence of CaCl₂, trimeric Spike bound to MBL with K_a (1/Ms)= $2.1e^{+4}$,
615 K_d (1/s)= $7.3e^{-4}$ and K_D =34 nM.

616 **Computational modeling of the MBL2 SARS-CoV-2 Spike interaction**

617 The model of the MBL2 trimer (UniProt(Consortium, 2020) P11226) was created
618 starting from the crystal structure of human mannose binding protein(Sheriff et al., 1994) (PDB
619 code 1HUP). The N-terminus of MBL2 was modeled as collagen, based on the template crystal
620 structure of collagen triple helix model(Berisio et al., 2002) (PDB code 1K6F). The binding
621 site of mannose molecules was determined aligning the MBL2 structure to the crystal structure

622 of rat mannose protein A(Ng et al., 2002) (PDB code 1KX1). Reference distances (~ 40 Å)
623 between mannose molecules were computed in PYMOL.

624 Putative binding sites of MBL2 were determined identifying all triplets of N-
625 glycosylation sites at a distance between 35 Å and 50 Å in the closed state SARS-CoV-2
626 (Casalino et al., 2020). Distances were computed using the program ALMOST(Fu et al., 2014).

627 **Pseudotyped virus production**

628 Human embryonic kidney 293T cells were transfected with a lentiviral vector
629 expressing the Green Fluorescent Protein (GFP) under the control of a human
630 Phosphoglycerate Kinase promoter (PGK) (Cesana et al., 2014) and a pCMV expressing vector
631 containing the SARS-CoV-2 Spike sequence (accession number MN908947) that was codon-
632 optimized for human expression and contained a deletion at the 3' end aimed at deleting 19
633 amino acid residues at the C-terminus. An HIV *gag-pol* packaging construct and a rev-
634 encoding plasmid were co-transfected by calcium phosphate for the production of infective
635 viral particles. 16 h after transfection, the medium was replaced and 30 h later, supernatant was
636 collected, filtered through 0.22 µm pore nitrocellulose filter and viral particles were pelleted
637 by ultracentrifugation. As control, lentivirus particles were pseudotyped with the VSV-g
638 glycoprotein that allows a high efficiency infection independently of binding to ACE2.

639 **Pseudotyped lentivirus binding assay**

640 96-well Nunc Maxisorp Immunoplates (Costar, USA) were coated with 100 µL of
641 rhMBL (3 and 1 µg/mL – 10 and 3.4 nM diluted in PBS). After overnight incubation, plates
642 were blocked with 2% BSA diluted in TBST-Ca²⁺ for 1 h at 37°C, washed three times with
643 TBST-Ca²⁺ and incubated for 1 h with 100 µL of SARS-CoV-2 Spike protein-pseudotyped
644 lentivirus or VSV-pseudotyped lentivirus (ranging from 0.1 to 1 µg/mL diluted in TBST- Ca²⁺).
645 After washing, bound pseudotyped virus particles were lysed with 0.5% Triton X-100 and HIV
646 p24 core protein was detected by ELISA (Perkin Elmer; USA).

647 **Complement deposition assay**

648 100 μ L of biotinylated SARS-CoV-2 Spike protein (either active trimer or non-covalent
649 trimer, 1 μ g/mL in PBS) were captured on 96 well plates for 1 h at 37°C. After washing, wells
650 were incubated for 1 h at 37°C with either 10% normal human serum (NHS, ComplemenTech
651 Inc, USA), 10% C1q-depleted serum (C1qDHS), 10% C4-depleted serum (C4DHS)
652 reconstituted or not with 25 μ g/mL purified C4 (Calbiochem, USA). 10% heat-inactivated
653 human serum (30' at 56°C, HI-NHS) and 10% C3-depleted serum (C3DHS) were used as
654 negative control. All the sera were diluted in 10 mM Tris-buffered saline containing 0.5 mM
655 MgCl₂, 2 mM CaCl₂ and 0.05% Tween-20, also used as washing buffer. For MBL
656 immunodepletion, 10% NHS was incubated overnight with 0.6 μ g/mL rabbit anti-MBL
657 antibody. Bound MBL-antibody complexes were separated by Dynabeads Protein G (Thermo
658 Fisher Scientific), and the supernatant (termed MBL-ID) was used in the assay (final
659 concentration, 10%). After washing, C5b-9 deposition was assayed by incubation for 1 h at
660 37°C with rabbit anti-sC5b-9 antibody (ComplemenTech Inc., Usa) diluted 1:2000 in washing
661 buffer as described before (Stravalaci et al., 2020), followed by specific HRP-conjugated
662 secondary antibody incubation and TMB development.

663 **Cell Lines**

664 The Vero and Vero E6 cell line was obtained from the Istituto Zooprofilattico of
665 Brescia, Italy, and ATCC, respectively. Cells were maintained in Eagle's minimum essential
666 medium (EMEM; Lonza) supplemented with 10% fetal bovine serum (FBS; Euroclone) and
667 penicillin-streptomycin (complete medium).

668 Human embryonic kidney 293T cells, a continuous human embryonic kidney cell line
669 containing the mutant gene of SV40 Large T Antigen (ATCC code CRL-3216), were cultured
670 as described (Follenzi et al., 2000).

671 The human lung epithelial Calu-3 cell line was obtained from NovusPharma. Cells were
672 grown in EMEM supplemented with 20% FBS and penicillin-streptomycin (complete
673 medium).

674 **Human Bronchial Epithelial Cells (HBEC)**

675 The isolation, culture, and differentiation of primary human bronchial epithelial cells
676 (HBECs) were performed as previously reported (Scudieri et al., 2012), with some
677 modifications. In brief, epithelial cells were obtained from mainstem human bronchi, derived
678 from individuals undergoing lung transplant. For the present study, cells were obtained from
679 three donors (BE37, BE63 and BE177). Epithelial cells were detached by overnight treatment
680 of bronchi with protease XIV and then were cultured in a serum-free medium (LHC9 mixed
681 with RPMI 1640, 1:1) containing supplements, as described (Scudieri et al., 2012). The
682 collection of bronchial epithelial cells and their study to investigate airway epithelium
683 physiopathology were specifically approved by the Ethics Committee of the Istituto Giannina
684 Gaslini following the guidelines of the Italian Ministry of Health (registration number:
685 ANTECER, 042-09/07/2018). Each patient provided informed consent to the study using a
686 form that was also approved by the Ethics Committee.

687 To obtain differentiated epithelia, cells were seeded at high density (5×10^5
688 cell/snapwell) on 12-mm diameter porous membranes (Snapwell inserts, Corning, code 3801).
689 After 24 hours, the serum-free medium was removed from both sides and, on the basolateral
690 side only, replaced with Pneumacult ALI medium (StemCell Technologies) and differentiation
691 of cells (for 3 weeks) was performed in air-liquid interface (ALI) condition.

692 **Entry assay with SARS-CoV-2 Spike- pseudotyped lentivirus particles**

693 293T cells were engineered to overexpress the SARS-CoV-2 entry receptor by
694 transduction of a lentiviral vector expressing ACE2 (kindly provided by Massimo Pizzato,
695 University of Trento). Lentiviral vector stock expressing ACE2 was produced as described

696 above. The entry assay was then optimized in 96-well plate by seeding 5×10^4 ACE2
697 overexpressing 293T cells/well. Twenty-four h later, cells and SARS-CoV-2 Spike-
698 pseudotyped lentivirus stock (1:500) were incubated with serial dilutions of soluble innate
699 immunity molecules for 30 min. The SARS-CoV-2 Spike-pseudotyped was added to the cells
700 and forty-eight h later, cells were treated with accutase, in order to detach them from the wells,
701 fixed and analyzed for GFP expression by cytofluorimetry.

702 **SARS-CoV-2 viral isolates**

703 The SARS-CoV-2 isolate of the B.1 lineage with the Spike D614G mutation (GISAID
704 accession ID: EPI_ISL_413489) was obtained from the nasopharyngeal swab of a mildly
705 symptomatic patient by inoculation of Vero E6 cells as described (Clementi et al., 2020;
706 Mycroft-West et al., 2020). The SARS-CoV-2 isolate of the South African B1.351 lineage
707 (GISAID accession ID: EPI_ISL_1599180) was obtained from the nasopharyngeal swab of an
708 Italian 80-year-old male patient. The SARS-CoV-2 isolate of the B1.1.7 lineage (GISAID
709 accession ID: EPI_ISL_1924880) was obtained from the nasopharyngeal swab of an Italian
710 58-year-old female patient. Secondary viral stocks were generated by infection of adherent
711 Vero E6 cells seeded in a 25 cm² tissue culture flask with 0.5 ml of the primary isolate diluted
712 in 5 ml of complete medium. Three days after infection, the supernatant was harvested and,
713 after centrifugation, passed through a 0.45 μ m filter. Aliquots of the secondary SARS-CoV-2
714 isolate were maintained at -80 °C. A plaque-forming assay was performed to determine viral
715 titers.

716 **Infections**

717 Calu-3 cells were seeded in 48-well plates (Corning) at the concentration of 5×10^4
718 cell/well in complete medium 24 h prior to infection. Ten-fold serial dilutions of MBL (from
719 0.01 to 10 μ g/ml – 0.034-34 nM) were incubated for 1 h with aliquots of SARS-CoV-2
720 containing supernatant to obtain a multiplicity of infection (MOI) of either 0.1 or 1 before

721 incubation with Calu-3 cells (Virus+MBL). After 48 and 72 h post-infection (PI), cell culture
722 supernatants were collected and stored at -80°C until determination of the viral titers by a
723 plaque-forming assay in Vero cells.

724 Virus incubation with MBL was also combined with incubation of target cells. Briefly,
725 virus incubation with MBL was performed as described above whereas Calu-3 cells were
726 incubated with 10-fold serial dilutions of MBL (from 0.01 to 10 $\mu\text{g}/\text{ml}$ – 0.034-34 nM). After
727 1 h, virus suspensions incubated with serial dilutions of MBL were added to MBL-treated cells
728 (Virus+ Cells+MBL). After 48 and 72 h POST, cell culture supernatants were collected and
729 stored at -80°C until determination of the viral titers by a plaque-forming assay in Vero cells.

730 Forty-eight h before infection, the apical surface of HBEC was washed with 500 μl of
731 PBS for 1.5 hours at 37°C , and the cultures were moved into fresh air liquid interface media.
732 Immediately before infection, apical surfaces were washed twice to remove accumulated
733 mucus with 500 μl of PBS with each wash lasting 30 min at 37°C . Two concentrations of either
734 PTX3 or MBL were added to the apical surface for 1 h prior to the addition of 100 μl of viral
735 inoculum (SARS-CoV-2) at a MOI of 1. HBEC were incubated for 2 h at 37°C . Viral inoculum
736 was then removed and the apical surface of the cultures was washed three times with 500 μl of
737 PBS. Cultures were incubated at 37°C for 72 h PI. Infectious virus produced by the HBEC was
738 collected by washing the apical surface of the culture with 100 μl of PBS every 24 h up to 72
739 h PI. Apical washes were stored at -80°C until analysis and titered by plaque assay in Vero
740 cells. At 72 h PI, cells were fixed in 4% paraformaldehyde for immunofluorescence analysis.

741 All infection experiments were performed in a biosafety level 3 (BSL-3) laboratory at the
742 Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University.

743 **Chemokine quantification**

744 Half of the ALI medium (1 ml) was collected from each well of the lower chamber
745 every 24 h PI and replaced with fresh ALI medium. The harvested medium was stored at -70

746 °C until analysis. Prior to chemokine quantification, 250 µl of medium was treated with 27 µl
747 of Triton X-100 and heated for 30 min at 56 °C to inactivate SARS-CoV-2 infectivity.

748 Chemokines (IL-8 and CXCL5) were quantified by ELISA (Quantikine ELISA kits,
749 code DY208, DY254, R&D Systems).

750 **Plaque-forming assay**

751 In order to measure the virus titer of the viral stocks, a plaque-forming assay was
752 optimized in Vero cells. Briefly, confluent Vero cells (1.5×10^6 cell/well) seeded in 6-well
753 plates (Corning) were incubated in duplicate with 1 ml of EMEM supplemented with 1% FBS
754 containing 10-fold serial dilutions of SARS-CoV-2 stock. After 1 h of incubation, the viral
755 inoculum was removed and methylcellulose (Sigma; 1 ml in EMEM supplemented with 5%
756 FBS) was overlaid on each well. After 4 days of incubation, the cells were stained with 1%
757 crystal violet (Sigma) in 70% methanol. The plaques were counted after examination with a
758 stereoscopic microscope (SMZ-1500; Nikon Instruments) and the virus titer was calculated in
759 terms of plaque forming units (PFU)/ml.

760 In order to determine the viral titers of the supernatant collected from Calu-3 cells at 48
761 and 72 h PI, confluent Vero cells (2.5×10^5 cell/well) were seeded in 24-well plates (Corning)
762 24 h prior to infection. Then, cells were incubated with 300 µl of EMEM supplemented with
763 1% FBS containing serially diluted (1:10) virus-containing supernatants. The plaque-forming
764 assay was performed as described above.

765 **Confocal and STED super-resolution microscopy**

766 After 4% PFA fixation, HBEC cultures were incubated for 1 h with PBS and 0.1%
767 Triton X-100 (Sigma-Aldrich), 5% normal donkey serum (Sigma-Aldrich), 2% BSA, 0.05%
768 Tween (blocking buffer). Cells were then incubated for 2 h in blocking buffer with the
769 following primary antibodies: mouse anti-cytokeratin 14 (Krt14) (#LL002; 1 µg/ml; cat. N° 33-
770 168, ProSci-Incorporated, US); rabbit polyclonal anti-Spike protein (944-1218aa) (2 µg/ml; cat.

771 N° 28867-1-AP, Proteintech[®], Germany); rat anti-MBL (#8G6; 1µg/ml; cat. N°HM1035,
772 Hycult[®]Biotech) and rat anti-MBL (#14D12; 1µg/ml; cat. N°HM1038, Hycult[®]Biotech). After
773 washing with PBS and 0.05% Tween, cells were incubated for 1 h with the following species-
774 specific cross-adsorbed secondary antibodies from Invitrogen-ThermoFisher Scientific:
775 donkey anti-rabbit IgG Alexa Fluor[®] 488 (1µg/ml; cat. N° A-21206); donkey anti-rat IgG
776 Alexa Fluor[®] 594 (1µg/ml; cat. N° A-21209); donkey anti-mouse IgG Alexa Fluor[®] 647
777 (1µg/ml; cat. N° A-31571). 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen) was used for
778 nucleus staining. Cells were mounted with Mowiol[®] (Sigma-Aldrich) and analyzed with a
779 Leica SP8 STED3X confocal microscope system equipped with a Leica HC PLAPO CS2
780 63X/1.40 oil immersion lens. Confocal images (1.024 X 1.024 pixels) were acquired in XYZ
781 and tiling modality (0.25 µm slice thickness) and at 1 Airy Unit (AU) of lateral resolution
782 (pinhole aperture of 95.5µm) at a frequency of 600Hz in bidirectional mode. Alexa Fluor 488[®]
783 was excited with a 488 nm argon laser and emission collected from 505 to 550nm. Alexa Fluor
784 594[®] was excited with a 594/604nm-tuned white light laser and emission collected from 580
785 to 620nm. Alexa Fluor 5647[®] was excited with a 640/648nm-tuned white light laser and
786 emission collected from 670 to 750nm. Frame sequential acquisition was applied to avoid
787 fluorescence overlap. A gating between 0.4 and 7ns was applied to avoid collection of
788 reflection and autofluorescence. 3D STED analysis was performed using the same acquisition
789 set-up. A 660 nm CW-depletion laser (30% of power) was used for excitations of Alexa Fluor
790 488[®] (Spike signal) and Alexa Fluor 594[®] (MBL signal). STED images were acquired with a
791 Leica HC PL APO 100×/1.40 oil STED White objective at 572.3 milli absorption unit (mAU).
792 CW-STED and gated CW-STED were applied to Alexa Fluor 488[®] and Alexa Fluor 594[®],
793 respectively. Confocal images were processed, 3D rendered and analyzed as colocalization rate
794 between Spike and MBL with Leica Application Suite X software (LASX; version
795 3.5.5.19976) and presented as medium intensity projection (MIP). STED images were de-

796 convolved with Huygens Professional software (Scientific Volume Imaging B. V.; version
797 19.10) and presented as MIP.

798 **Patient cohorts for genetic analyses**

799 For association analyses, we investigated a total of 2,000 individuals. These included:
800 i) 332 patients with severe COVID-19, which was defined as hospitalization with respiratory
801 failure and a confirmed SARS-CoV-2 viral RNA PCR test from nasopharyngeal swabs.
802 Patients were recruited from intensive care units and general wards at two hospitals in the
803 Milan area, i.e., the Humanitas Clinical and Research Center, IRCCS, in Rozzano, Italy (140
804 patients); and San Gerardo Hospital, in Monza, Italy (192 patients); ii) 1,668 controls from the
805 general Italian population with unknown COVID-19 status.

806 Details on DNA extraction, array genotyping and quality checks are reported elsewhere
807 (Myocardial Infarction Genetics et al., 2009; Severe Covid et al., 2020). The dataset for cases
808 was submitted to the European Bioinformatics Institute (www.ebi.ac.uk/gwas) under accession
809 numbers GCST90000255 and GCST90000256, whereas the dataset for controls is deposited in
810 the Genotypes and Phenotypes database (dbGaP; <https://www.ncbi.nlm.nih.gov/gap/>), under
811 the phs000294.v1.p1 accession code.

812 Approvals for the project were obtained from the relevant ethics committees
813 (Humanitas Clinical and Research Center, reference number, 316/20; the University of Milano-
814 Bicocca School of Medicine, San Gerardo Hospital, reference number, 84/2020).

815 **Imputation**

816 Genetic coverage was increased by performing single-nucleotide polymorphism (SNP)
817 imputation on the genome build GRCh38 using the Michigan Imputation Server
818 (<https://imputation.biodatacatalyst.nhlbi.nih.gov/index.html#!>) and haplotypes generated by
819 the Trans-Omics for Precision Medicine (TOPMed) program (freeze 5) (Taliun et al., 2021),
820 for both cases and controls. In the imputation, we used the population panel “ALL” and applied

821 the server options to filter by an imputation of $R^2 > 0.1$. In the post-imputation steps, we only
822 retained those SNPs with $R^2 \geq 0.6$ and minor allele frequency (MAF) $\geq 1\%$. Next, we accurately
823 checked cases and controls for solving within-Italian relationships and for testing the possible
824 existence of population stratification within and across batches: to this aim, we performed
825 principal component analysis (PCA), using a LD-pruned subset of SNPs across chromosome
826 10 and the Plink v.1.9 package (Chang et al., 2015). The final set of analyzed variants
827 comprised 3,425 SNPs, distributed in the *MBL2* region (the gene +/-500 kb).

828 **Statistical analysis**

829 Prism GraphPad software v. 8.0 (www.graphpad.com) was used for the statistical
830 analyses. Comparison among groups were performed using one or two-way analysis of
831 variance (ANOVA) and the Bonferroni's correction. Non-linear fit of transformed data was
832 determined by using the log (agonist) vs. response (three or four parameters).

833 For genetic studies, case-control allele-dose association tests were performed using the
834 PLINK v.1.9 logistic-regression framework for dosage data. Age, sex, age*age, sex*age, and
835 the first 10 principal components from PCA were introduced in the model as covariates.
836 Analyses were conducted always referring to the minor allele. All P values are presented as not
837 corrected and accompanied by odds ratio (OR) and 95% confidence interval (CI); however, in
838 the relevant table/figure, Bonferroni-corrected thresholds for significance are indicated in the
839 footnote/legend.

840 Haplotype analysis was performed in two ways: i) by selecting relevant SNPs and using
841 the `-hap-logistic` option implemented in PLINK v.1.07 (Purcell et al., 2007); ii) by an
842 unsupervised approach by means of the Beagle software v3.3
843 (<http://faculty.washington.edu/browning/beagle/b3.html>), which uses the method described by
844 Browning & Browning (Browning and Browning, 2007) for inferring haplotype phase. In this
845 case, we used the default setting of 1,000 permutations for calculating corrected P values.

846 In the meta-analysis, we took advantage of association data deposited in the Regeneron
847 – Genetic Center database (<https://rgc-covid19.regeneron.com/home>) for the GHS study
848 (Geisinger Health System; data available for 869 cases and 112,862 controls of European
849 ancestry). Pooled Ors and Cis were calculated using the Mantel-Haenszel model (Mantel and
850 Haenszel, 1959)
851

852 **Supplementary information**

853

854 **Supplementary Table 1. Recombinant SARS-CoV-2 proteins used in this study.**


| Proteins | Host | Cat | Company |
|---|----------------|---------------|---------------------------|
| SARS-CoV-2 S1 protein, His Tag | HEK293 | S1N-C52H4 | ACROBiosystems |
| SARS-CoV-2 S2 protein, His Tag | HEK293 | S2N-C52H5 | ACROBiosystems |
| SARS-CoV-2 S protein, His Tag, active trimer | HEK293 | SPN-C52H8 | ACROBiosystems |
| SARS-CoV-2 Nucleocapsid protein, His Tag | HEK293 | NUN-C5227 | ACROBiosystems |
| SARS-CoV-2 Envelope protein. GST, His Tag | <i>E.coli</i> | ENN-C5128 | ACROBiosystems |
| Biotinylated SARS-CoV-2 S protein, His Tag, active trimer | HEK293 | SPN-C82E3 | ACROBiosystems |
| Biotinlyated SARS-CoV-2 Nucleocapsid protein, His Tag | HEK293 | NUN-C82E8 | ACROBiosystems |
| SARS-CoV-2 S protein, His Tag | HEK293 | 10549-CV | R&D Systems |
| SARS-CoV-2 Nucleocapsid protein, His Tag | HEK293 | 230-30164 | RayBiotech |
| SARS-CoV-2 S protein, His Tag | HEK293 | In house | (Andreano et al., 2020) |
| SARS-CoV-2 S protein trimer, His Tag | EXPI293F cells | In house | (De Gasparo et al., 2021) |
| SARS-CoV-2 S protein, His Tag | CHO | XLGCOV-1-PPTH | ExcellGene |
| SARS-CoV-2 (2019-nCoV) Spike RBD, His Tag | HEK293 | 40592-V08H | Sino Biological |
| SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD, His Tag | Insect cells | 40589-V08B1 | Sino Biological |
| SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD (B.1.1.7), His Tag | Insect cells | 40589-V08B6 | Sino Biological |
| SARS-CoV-2 S protein (D614G), His Tag | HEK293 | SPN-C52H3 | ACROBiosystems |
| SARS-CoV-2 S protein (B.1.1.7 variant), His Tag | HEK293 | SPN-C52H6 | ACROBiosystems |
| SARS-CoV-2 S protein (B.1.351 variant), His Tag | HEK293 | SPN-C52Hc | ACROBiosystems |
| SARS-CoV-2 S protein (B.1.1.28 variant), His Tag | HEK293 | SPN-C52Hg | ACROBiosystems |

855

856

857

858 **Supplementary Figures**



859


860 **Supplementary Figure 1.** Binding of PTX3 to captured SARS-CoV-2 Nucleocapsid

861 proteins from different companies. Data are presented as mean \pm SEM of one experiment

862 performed in duplicate.

863

864




865

866 **Supplementary Figure 2.** Interaction between recombinant RBD and immobilized MBL in

867 the presence or absence of calcium, as assessed by SPR analysis.

868

869



870

871 **Supplementary Figure 3.** Inhibition of viral infection and chemokine production by MBL.

872 (A-C) Inhibition of the infectivity of the D614G (isolate EPI_ISL_413489) (A, B) and B.1.1.7

873 (C) SARS-CoV-2 variants by MBL in Calu-3 cells. SARS-CoV-2 (A upper panel, B and C,

874 MOI=0.1; A lower panels, MOI=1) was preincubated in complete medium containing different
875 concentrations of MBL (0.01–10 µg/mL– 0.034–34 nM) before incubation with Calu-3 cells
876 (Virus + MBL) (A), or both virus and cells were pre-incubated with the same concentrations
877 of MBL (Virus+ Cells+MBL) (B, C). After 48 and 72 h, the infectivity of SARS-CoV-2 present
878 in cell culture supernatants was determined by a plaque-forming assay in Vero cells. NIL: no
879 MBL. (D) SARS-CoV-2 production at the HBEC apical surface at 72 h PI, in the presence of
880 25 or 100 µg/ml (75 or 300 nM) PTX3. (E) Chemokine production by SARS-CoV-2 infected
881 HBEC in the presence of MBL. Mean values of two (A, B, D) or one (C, E) experiments in
882 duplicate cell culture are shown. ****p value <0.0001, ***p value <0.001, **p value <0.01 as
883 determined by two-way (A, B, C, E) or one-way (D) ANOVA with Bonferroni's correction.

884

885

886 **Movie S1. SARS-CoV-2 S protein and MBL colocalized on infected HBEC cells.** 3D
887 rendering showing a blended reconstruction of the colocalization between SARS-CoV-2 S
888 protein and MBL in HBEC cultures, preferentially associated to the apical side.

889

890 **References**

- 891 Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N.V., Paciello, I.,
892 Monego, S.D., Pantano, E., Manganaro, N., Manenti, A., *et al.* (2020). SARS-CoV-2 escape
893 in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv.
894 doi.org/10.1101/2020.12.28.424451.
- 895 Berisio, R., Vitagliano, L., Mazzarella, L., and Zagari, A. (2002). Crystal structure of
896 the collagen triple helix model [(Pro-Pro-Gly)(10)](3). *Protein Sci* 11, 262-270.
- 897 Bottazzi, B., Doni, A., Garlanda, C., and Mantovani, A. (2010). An integrated view of
898 humoral innate immunity: pentraxins as a paradigm. *Annu Rev Immunol* 28, 157-183.
- 899 Bottazzi, B., Vouret-Craviari, V., Bastone, A., De Gioia, L., Matteucci, C., Peri, G.,
900 Spreafico, F., Pausa, M., D'Ettore, C., Gianazza, E., *et al.* (1997). Multimer formation and
901 ligand recognition by the long pentraxin PTX3. Similarities and differences with the short
902 pentraxins C-reactive protein and serum amyloid P component. *J Biol Chem* 272, 32817-
903 32823.
- 904 Bozza, S., Bistoni, F., Gaziano, R., Pitzurra, L., Zelante, T., Bonifazi, P., Perruccio,
905 K., Bellocchio, S., Neri, M., Iorio, A.M., *et al.* (2006). Pentraxin 3 protects from MCMV
906 infection and reactivation through TLR sensing pathways leading to IRF3 activation. *Blood*
907 108, 3387-3396.
- 908 Browning, S.R., and Browning, B.L. (2007). Rapid and accurate haplotype phasing
909 and missing-data inference for whole-genome association studies by use of localized
910 haplotype clustering. *Am J Hum Genet* 81, 1084-1097.
- 911 Brunetta, E., Folci, M., Bottazzi, B., De Santis, M., Gritti, G., Protti, A., Mapelli,
912 S.N., Bonovas, S., Piovani, D., Leone, R., *et al.* (2021). Macrophage expression and
913 prognostic significance of the long pentraxin PTX3 in COVID-19. *Nat Immunol* 22, 19-24.
- 914 Carvelli, J., Demaria, O., Vely, F., Batista, L., Chouaki Benmansour, N., Fares, J.,
915 Carpentier, S., Thibult, M.L., Morel, A., Remark, R., *et al.* (2020). Association of COVID-19
916 inflammation with activation of the C5a-C5aR1 axis. *Nature* 588, 146-150.
- 917 Casalino, L., Gaieb, Z., Goldsmith, J.A., Hjorth, C.K., Dommer, A.C., Harbison,
918 A.M., Fogarty, C.A., Barros, E.P., Taylor, B.C., McLellan, J.S., *et al.* (2020). Beyond
919 Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. *ACS Cent Sci* 6, 1722-
920 1734.

921 Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella,
922 S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., *et al.* (2014). Uncovering and dissecting the
923 genotoxicity of self-inactivating lentiviral vectors in vivo. *Mol Ther* 22, 774-785.

924 Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J.
925 (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets.
926 *Gigascience* 4, 7.

927 Chiodo, F., Bruijns, S.C.M., Rodriguez, E., Li, R.J.E., Molinaro, A., Silipo, A., Di
928 Lorenzo, F., Garcia-Rivera, D., Valdes-Balbin, Y., Verez-Bencomo, V., *et al.* (2020). Novel
929 ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins
930 and Lung Microbiota. *bioRxiv*, doi.org/10.1101/2020.05.13.092478.

931 Chu, H., Chan, J.F., Yuen, T.T., Shuai, H., Yuan, S., Wang, Y., Hu, B., Yip, C.C.,
932 Tsang, J.O., Huang, X., *et al.* (2020). Comparative tropism, replication kinetics, and cell
933 damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical
934 manifestations, transmissibility, and laboratory studies of COVID-19: an observational study.
935 *Lancet Microbe* 1, e14-e23.

936 Clementi, N., Criscuolo, E., Diotti, R.A., Ferrarese, R., Castelli, M., Dagna, L.,
937 Burioni, R., Clementi, M., and Mancini, N. (2020). Combined Prophylactic and Therapeutic
938 Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. *Front Microbiol* 11,
939 1704.

940 Consortium, T.U. (2020). UniProt: the universal protein knowledgebase in 2021.
941 *Nucleic Acids Res* 49, D480-D489.

942 De Gasparo, R., Pedotti, M., Simonelli, L., Nickl, P., Muecksch, F., Cassaniti, I.,
943 Percivalle, E., Lorenzi, J.C.C., Mazzola, F., Magri, D., *et al.* (2021). Bispecific IgG
944 neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature* 593, 424-428.

945 Desmyter, J., Melnick, J.L., and Rawls, W.E. (1968). Defectiveness of interferon
946 production and of rubella virus interference in a line of African green monkey kidney cells
947 (Vero). *J Virol* 2, 955-961.

948 Fajgenbaum, D.C., and June, C.H. (2020). Cytokine Storm. *N Engl J Med* 383, 2255-
949 2273.

950 Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. (2000). Gene
951 transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol
952 sequences. *Nat Genet* 25, 217-222.

953 Fu, B., Sahakyan, A.B., Camilloni, C., Tartaglia, G.G., Paci, E., Caflisch, A.,
954 Vendruscolo, M., and Cavalli, A. (2014). ALMOST: an all atom molecular simulation toolkit
955 for protein structure determination. *J Comput Chem* 35, 1101-1105.

956 Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z.,
957 Hu, Y., *et al.* (2020). Highly pathogenic coronavirus N protein aggravates lung injury by
958 MASP-2-mediated complement over-activation. medRxiv,
959 10.1101/2020.1103.1129.20041962.

960 Garlanda, C., Bottazzi, B., Magrini, E., Inforzato, A., and Mantovani, A. (2018).
961 PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and
962 Cancer. *Physiol Rev* 98, 623-639.

963 Garred, P., Pressler, T., Lanng, S., Madsen, H.O., Moser, C., Laursen, I., Balstrup, F.,
964 Koch, C., and Koch, C. (2002). Mannose-binding lectin (MBL) therapy in an MBL-deficient
965 patient with severe cystic fibrosis lung disease. *Pediatr Pulmonol* 33, 201-207.

966 Han, B., Ma, X., Zhang, J., Zhang, Y., Bai, X., Hwang, D.M., Keshavjee, S., Levy,
967 G.A., McGilvray, I., and Liu, M. (2012). Protective effects of long pentraxin PTX3 on lung
968 injury in a severe acute respiratory syndrome model in mice. *Lab Invest* 92, 1285-1296.

969 Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J.M., and Glaunsinger, B.A.
970 (2020). The molecular virology of coronaviruses. *J Biol Chem* 295, 12910-12934.

971 Holmskov, U., Thiel, S., and Jensenius, J.C. (2003). Collections and ficolins: humoral
972 lectins of the innate immune defense. *Annu Rev Immunol* 21, 547-578.

973 Ip, W.K., Chan, K.H., Law, H.K., Tso, G.H., Kong, E.K., Wong, W.H., To, Y.F.,
974 Yung, R.W., Chow, E.Y., Au, K.L., *et al.* (2005). Mannose-binding lectin in severe acute
975 respiratory syndrome coronavirus infection. *J Infect Dis* 191, 1697-1704.

976 Jensenius, J.C., Jensen, P.H., McGuire, K., Larsen, J.L., and Thiel, S. (2003).
977 Recombinant mannan-binding lectin (MBL) for therapy. *Biochem Soc Trans* 31, 763-767.

978 Karwaciak, I., Salkowska, A., Karas, K., Dastych, J., and Ratajewski, M. (2021).
979 Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes
980 and Macrophages-Potential Implications for Cytokine Storm Syndrome. *Vaccines (Basel)* 9,
981 54.

982 King, C., and Sprent, J. (2021). Dual Nature of Type I Interferons in SARS-CoV-2-
983 Induced Inflammation. *Trends Immunol* 42, 312-322.

984 Koch, A., Melbye, M., Sorensen, P., Homoe, P., Madsen, H.O., Molbak, K., Hansen,
985 C.H., Andersen, L.H., Hahn, G.W., and Garred, P. (2001). Acute respiratory tract infections
986 and mannose-binding lectin insufficiency during early childhood. *JAMA* 285, 1316-1321.

- 987 Lempp, F.A., Soriaga, L., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J.,
988 Bianchi, S., Walls, A.C., Bowen, J.E., Zhou, J., *et al.* (2021). Membrane lectins enhance
989 SARS-CoV-2 infection and influence the neutralizing activity of different classes of
990 antibodies. *bioRxiv*, doi.org/10.1101/2021.04.03.438258.
- 991 Lipscombe, R.J., Sumiya, M., Hill, A.V., Lau, Y.L., Levinsky, R.J., Summerfield,
992 J.A., and Turner, M.W. (1992). High frequencies in African and non-African populations of
993 independent mutations in the mannose binding protein gene. *Hum Mol Genet* *1*, 709-715.
- 994 Lu, Q., Liu, J., Zhao, S., Gomez Castro, M.F., Laurent-Rolle, M., Dong, J., Ran, X.,
995 Damani-Yokota, P., Tang, H., Karakousi, T., *et al.* (2021). SARS-CoV-2 exacerbates
996 proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety
997 family member 2. *Immunity*. doi: 10.1016/j.immuni.2021.05.006. In press.
- 998 Madsen, H.O., Garred, P., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., Thiel, S., and
999 Svejgaard, A. (1994). A new frequent allele is the missing link in the structural
1000 polymorphism of the human mannan-binding protein. *Immunogenetics* *40*, 37-44.
- 1001 Madsen, H.O., Garred, P., Thiel, S., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., and
1002 Svejgaard, A. (1995). Interplay between promoter and structural gene variants control basal
1003 serum level of mannan-binding protein. *J Immunol* *155*, 3013-3020.
- 1004 Mantel, N., and Haenszel, W. (1959). Statistical aspects of the analysis of data from
1005 retrospective studies of disease. *J Natl Cancer Inst* *22*, 719-748.
- 1006 McBride, R., van Zyl, M., and Fielding, B.C. (2014). The coronavirus nucleocapsid is
1007 a multifunctional protein. *Viruses* *6*, 2991-3018.
- 1008 Medetalibeyoglu, A., Bahat, G., Senkal, N., Kose, M., Avci, K., Sayin, G.Y., Isoglu-
1009 Alkac, U., Tukek, T., and Pehlivan, S. (2021). Mannose binding lectin gene 2 (rs1800450)
1010 missense variant may contribute to development and severity of COVID-19 infection. *Infect*
1011 *Genet Evol* *89*, 104717.
- 1012 Merad, M., and Martin, J.C. (2020). Pathological inflammation in patients with
1013 COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol* *20*, 355-362.
- 1014 Mycroft-West, C.J., Su, D., Pagani, I., Rudd, T.R., Elli, S., Gandhi, N.S., Guimond,
1015 S.E., Miller, G.J., Meneghetti, M.C.Z., Nader, H.B., *et al.* (2020). Heparin Inhibits Cellular
1016 Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1
1017 Receptor-Binding Domain with Heparin. *Thromb Haemost* *120*, 1700-1715.
- 1018 Myocardial Infarction Genetics, C., Kathiresan, S., Voight, B.F., Purcell, S.,
1019 Musunuru, K., Ardisino, D., Mannucci, P.M., Anand, S., Engert, J.C., Samani, N.J., *et al.*

1020 (2009). Genome-wide association of early-onset myocardial infarction with single nucleotide
1021 polymorphisms and copy number variants. *Nat Genet* *41*, 334-341.

1022 Ng, K.K., Kolatkar, A.R., Park-Snyder, S., Feinberg, H., Clark, D.A., Drickamer, K.,
1023 and Weis, W.I. (2002). Orientation of bound ligands in mannose-binding proteins.
1024 Implications for multivalent ligand recognition. *J Biol Chem* *277*, 16088-16095.

1025 Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D.,
1026 Walker, S., Parkinson, N., Fourman, M.H., Russell, C.D., *et al.* (2021). Genetic mechanisms
1027 of critical illness in COVID-19. *Nature* *591*, 92-98.

1028 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D.,
1029 Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., *et al.* (2007). PLINK: a tool set for whole-
1030 genome association and population-based linkage analyses. *Am J Hum Genet* *81*, 559-575.

1031 Reading, P.C., Bozza, S., Gilbertson, B., Tate, M., Moretti, S., Job, E.R., Crouch,
1032 E.C., Brooks, A.G., Brown, L.E., Bottazzi, B., *et al.* (2008). Antiviral Activity of the Long
1033 Chain Pentraxin PTX3 against Influenza Viruses. *J Immunol* *180*, 3391-3398.

1034 Risitano, A.M., Mastellos, D.C., Huber-Lang, M., Yancopoulou, D., Garlanda, C.,
1035 Ciceri, F., and Lambris, J.D. (2020). Complement as a target in COVID-19? *Nat Rev*
1036 *Immunol* *20*, 343-344.

1037 Schirinzi, A., Pesce, F., Laterza, R., D'Alise, M.G., Lovero, R., Fontana, A., Contino,
1038 R., and Di Serio, F. (2021). Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients
1039 admitted to the emergency department. *J Infect* *82*, 84-123.

1040 Scudieri, P., Caci, E., Bruno, S., Ferrera, L., Schiavon, M., Sondo, E., Tomati, V.,
1041 Gianotti, A., Zegarra-Moran, O., Pedemonte, N., *et al.* (2012). Association of TMEM16A
1042 chloride channel overexpression with airway goblet cell metaplasia. *J Physiol* *590*, 6141-
1043 6155.

1044 Severe Covid, G.G., Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos,
1045 A., Invernizzi, P., Fernandez, J., Prati, D., Baselli, G., *et al.* (2020). Genomewide Association
1046 Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med* *383*, 1522-1534.

1047 Sheriff, S., Chang, C.Y., and Ezekowitz, R.A.B. (1994). Human mannose-binding
1048 protein carbohydrate recognition domain trimerizes through a triple α -helical coiled-coil. *Nat*
1049 *Struct Biol* *1*, 789-794.

1050 Stravalaci, M., Davi, F., Parente, R., Gobbi, M., Bottazzi, B., Mantovani, A., Day,
1051 A.J., Clark, S.J., Romano, M.R., and Inforzato, A. (2020). Control of Complement Activation
1052 by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration. *Front*
1053 *Pharmacol* *11*, 591908.

- 1054 Sumiya, M., Super, M., Tabona, P., Levinsky, R.J., Arai, T., Turner, M.W., and
1055 Summerfield, J.A. (1991). Molecular basis of opsonic defect in immunodeficient children.
1056 *Lancet* 337, 1569-1570.
- 1057 Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun,
1058 S.A.G., Corvelo, A., Gogarten, S.M., Kang, H.M., *et al.* (2021). Sequencing of 53,831
1059 diverse genomes from the NHLBI TOPMed Program. *Nature* 590, 290-299.
- 1060 Wang, J., Jiang, M., Chen, X., and Montaner, L.J. (2020). Cytokine storm and
1061 leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19
1062 patients in China and emerging pathogenesis and therapy concepts. *J Leukoc Biol* 108, 17-41.
- 1063 Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S., and Crispin, M. (2020). Site-
1064 specific glycan analysis of the SARS-CoV-2 spike. *Science* 369, 330-333.
- 1065 Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W.,
1066 Tian, J.H., Pei, Y.Y., *et al.* (2020). A new coronavirus associated with human respiratory
1067 disease in China. *Nature* 579, 265-269.
- 1068 Yuan, F.F., Tanner, J., Chan, P.K., Biffin, S., Dyer, W.B., Geczy, A.F., Tang, J.W.,
1069 Hui, D.S., Sung, J.J., and Sullivan, J.S. (2005). Influence of FcγRIIA and MBL
1070 polymorphisms on severe acute respiratory syndrome. *Tissue Antigens* 66, 291-296.
- 1071 Zeng, W., Liu, G., Ma, H., Zhao, D., Yang, Y., Liu, M., Mohammed, A., Zhao, C.,
1072 Yang, Y., Xie, J., *et al.* (2020). Biochemical characterization of SARS-CoV-2 nucleocapsid
1073 protein. *Biochem Biophys Res Commun* 527, 618-623.
- 1074 Zhang, H., Zhou, G., Zhi, L., Yang, H., Zhai, Y., Dong, X., Zhang, X., Gao, X., Zhu,
1075 Y., and He, F. (2005). Association between mannose-binding lectin gene polymorphisms and
1076 susceptibility to severe acute respiratory syndrome coronavirus infection. *J Infect Dis* 192,
1077 1355-1361.
- 1078 Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M.,
1079 Sabli, I.K.D., Hodeib, S., Korol, C., *et al.* (2020). Inborn errors of type I IFN immunity in
1080 patients with life-threatening COVID-19. *Science* 370, eabd4570.
- 1081 Zhou, Y., Lu, K., Pfefferle, S., Bertram, S., Glowacka, I., Drosten, C., Pohlmann, S.,
1082 and Simmons, G. (2010). A single asparagine-linked glycosylation site of the severe acute
1083 respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-
1084 binding lectin through multiple mechanisms. *J Virol* 84, 8753-8764.
- 1085 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi,
1086 W., Lu, R., *et al.* (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019.
1087 *N Engl J Med* 382, 727-733.

